PERSISTENCE RATE WITH SUBCUTANEOUS BIOLOGIC THERAPIES IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA)

被引：0
|
作者：
Lyu, R. [1 ]
Ding, Q. [2 ]
Govoni, M. [3 ]
Fan, T. [1 ]
机构：
[1] Merck & Co Inc, Whitehouse Stn, NJ USA
[2] Temple Univ, Philadelphia, PA 19122 USA
[3] Merck Sharp & Dohme Ltd, Rome, Italy
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMS64
引用
收藏
页码：A384 / A384
页数：1
相关论文
共 50 条
  • [41] Preferences for treatment with biologic agents in rheumatoid arthritis (RA).
    Constantinescu, Florina
    Wani, Shoba
    Gaucher, Susan
    Weinstein, Arthur
    Fraenkel, Liana
    ARTHRITIS AND RHEUMATISM, 2006, 54 (12): : 4096 - 4096
  • [42] Why subcutaneous methotrexate should be a prerequisite to biologic use in patients with rheumatoid arthritis
    Koduri, Gouri M.
    Mukhtyar, Chetan
    RHEUMATOLOGY, 2019, 58 (04) : 559 - 560
  • [43] Cost of Biologic Treatment Persistence or Switching in Rheumatoid Arthritis
    Gu, Tao
    Mutebi, Alex
    Stolshek, Bradley S.
    Tan, Hiangkiat
    AMERICAN JOURNAL OF MANAGED CARE, 2018, 24 (08): : SP338 - SP345
  • [44] PERSISTENCE WITH BIOLOGIC AGENTS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN JAPAN
    Mahlich, J. C.
    Sruamsiri, R.
    VALUE IN HEALTH, 2016, 19 (07) : A918 - A918
  • [45] Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan
    Mahlich, Joerg
    Sruamsiri, Rosarin
    PATIENT PREFERENCE AND ADHERENCE, 2016, 10 : 1509 - 1518
  • [46] ETHNICITY IS ASSOCIATED WITH BIOLOGIC TREATMENT PERSISTENCE IN RHEUMATOID ARTHRITIS
    Kumar, K.
    Sahbudin, I.
    Filer, A.
    Buckley, C. D.
    Raza, K.
    Stack, R.
    Nightingale, P.
    Deeming, A.
    Situnayake, D.
    de Pablo, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 483 - 483
  • [47] Predictors of Initiating Biologic Monotherapy in Biologic Naive Patients with Rheumatoid Arthritis (RA) in a US Registry Population
    Pappas, Dimitrios A.
    Reed, George W.
    John, Ani
    Shewade, Ashwini
    Saunders, Katherine C.
    Devenport, Jenny
    Greenberg, Jeffrey D.
    Kremer, Joel M.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S214 - S215
  • [48] IMPAIRMENTS IN QUALITY OF LIFE, DAILY FUNCTION, AND WORK PRODUCTIVITY AND ACTIVITY IN RHEUMATOID ARTHRITIS PATIENTS WHO USE SUBCUTANEOUS BIOLOGIC THERAPIES
    Tang, B.
    Naim, A.
    McKenzie, R. S.
    Bailey, R.
    Freedman, D.
    Wagner, S.
    Piech, C. T.
    VALUE IN HEALTH, 2009, 12 (03) : A70 - A71
  • [49] Drug persistence rate of leflunomide(LEF) in rheumatoid arthritis (RA) patients treated by private practice rheumatologists in Switzerland
    Russ, WJ
    Von Kempis, J
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 154 - 155
  • [50] Impact of patient's out-of-pocket cost on adherence and persistence with biologic therapies for rheumatoid arthritis
    Gleeson, M.
    Curkendall, S.
    Patel, V
    Smith, R.
    Zagari, M.
    VALUE IN HEALTH, 2007, 10 (03) : A119 - A120
12345